Characterization of cell-free circulating DNA in plasma in patients with prostate cancer

Autor(es)

Delgado, Pamela Oliveira ^[1] ; Alves, Beatriz Costa A. ^[1] ; Gehrke, Flavia de Sousa ^[1] ; Kuniyoshi, Renata Kelly ^[1] ; Wroclavski, Marcelo Langer ^[2] ; Del Giglio, Auro ^[1] ; Affonso Fonseca, Fernando Luiz ^{[3, 1]}

Afiliação do(s) autor(es)

^[1] FMABC, Oncol Hematol Discipline, Sao Paulo - Brazil

^[2] FMABC, Urol Discipline, Sao Paulo - Brazil

^[3] Univ Fed Sao Paulo, Dept Biol Sci, Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: TUMOR BIOLOGY; v. 34, n. 2, p. 983-986, APR 2013.
• Citações Web of Science: 40

Resumo

Cell-free circulating DNA in plasma and serum may serve as a biomarker for malignant tumor detection and follow up in patients with a variety of solid tumors including prostate cancer. In healthy patients, DNA is normally released from an apoptotic source which generates small fragments of cell-free DNA, whereas cancer patients have cell-free circulating DNA that originated from necrosis, autophagy, or mitotic catastrophe. Cell-free circulating DNA levels were measured by a quantitative real-time PCR method with a set of primers targeted to amplify the consensus ALU apoptotic versus necrotic origin. Prostate cancer patients before and 3 months after diagnosis showed cell-free circulating DNA released at apoptotic and non-apoptotic cell death. Interestingly, all patients after 6 months demonstrated DNA released at non-apoptotic cell. The principal source of cell-free circulating DNA is of apoptotic and non-apoptotic cell death. However, during treatment, this feature could change. Therefore, the study of cell-free circulating DNA would be important to follow the evolution of the disease during the treatment. (AU)

• Processo FAPESP: 10/50490-6 - Avaliacao da e-cadherina e metaloproteinase 13 em amostras plasmaticas de pacientes portadores de adenocarcinoma prostatico.
• Beneficiário: Fernando Luiz Affonso Fonseca
• Modalidade de apoio: Auxílio à Pesquisa - Regular